|
業務類別
|
Biotechnology |
|
業務概覽
|
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. |
| 公司地址
| 7-11 boulevard Haussmann, Paris, FRA, 75009 |
| 電話號碼
| +33 153830963 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.abivax.com |
| 員工數量
| 69 |
| Mr. Marc de Garidel |
Chief Executive Officer and Chairman of the Board |
-- |
05/04/2024 |
| Mr. Didier Blondel |
Chief Financial Officer and Secretary of the Board |
-- |
05/04/2024 |
| Ms. Ida Hatoum |
Chief People Officer |
-- |
05/04/2024 |
| Mr. Didier Scherrer |
Chief Scientific Officer |
-- |
05/04/2024 |
| Mr. Michael Ferguson |
Chief Commercial Officer |
-- |
05/04/2024 |
| Mr. Pierre Courteille |
Chief Business Officer |
-- |
05/04/2024 |
| Mr. Sheldon Sloan |
Chief Medical Officer |
-- |
05/04/2024 |
|
|
| Mr. Troy A. Ignelzi |
Independent Director |
05/04/2024 |
| Dr. Carol L. Brosgart, M.D. |
Independent Director |
05/04/2024 |
| Dr. June Lee, M.D. |
Independent Director |
05/04/2024 |
| Dr. Philippe Pouletty |
Director |
05/04/2024 |
| Ms. Corinna zur Bonsen-Thomas |
Independent Director |
05/04/2024 |
| Mr. Kinam Hong |
Independent Director |
05/04/2024 |
| Mr. Marc de Garidel |
Chief Executive Officer and Chairman of the Board |
05/04/2024 |
| Ms. Camilla Soenderby |
Independent Director |
05/04/2024 |
|
|
|
|
